1. Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M. Oral tranexamic acid for the treatment of melasma: a review. Dermatol Surg. 2018; 44(6): 814-825.

2. Kim HJ, Moon SH, Cho SH, Lee JD, Sung Kim H. Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review. Acta Derm Venereol. 2017; 97(6-7): 776-781.

3. Del Rosario E, Florez-Pollack S, Zapata Jr L, Hernandez K, Tovar-Garza A, Rodrigues M, et al. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. J Am Acad Dermatol. 2018; 78(2): 363-369.

4. Sharma R, Mahajan VK, Mehta KS, Chauhan PS, Rawat R, Shiny TN. Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study. Clin Exp Dermatol. 2017; 42(7): 728-734.

5. Wang JV, Jhawar N, Saedi N. Tranexamic Acid for Melasma: Evaluating the Various Formulations. J Clinical Aesthetic Dermatol. 2019; 12(8): E73-E74.

6. Tadir Y, Gaspar A, Lev-Sagie A, Alexiades M, Alinsod R, Bader A, et al. Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med. 2017; 49(2):137-159.

7. González Isaza P, Jaguszewska K, Cardona JL, Lukaszuk M. Long-term effect of thermoablative fractional CO2 laser treatment as a novel approach to urinary incontinence management in women with genitourinary syndrome of menopause. Int Urogynecol J. 2018; 29(2): 211-215.

8. Zerbinati N, Serati M, Origoni M, Candiani M, Lannitti T. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 2015; 30(1): 429-436.

9. Sokol ER, Karram M. An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause. 2016; 23(10): 1102-1107.

10. Agarwal P, Rashighi M, Essien KI, Richmond J, Randall L, Pazoki-Toroudi H, et al. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J Invest Dermatol. 2015; 135(4): 1080-1088.

11. Vanderweil SG, Amano S, Ko WC, Richmond J, Kelley M, Makredes Senna M, et al. A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol. 2017; 76(1):150-151.

12. Iraji F, Banihashemi SH, Faghihi G, Shahmorad Z, Tajmirriahi N, Bokaie Jazi S. A comparison of betamethasone valerate 0.1% cream twice daily plus oral simvastatin versus betamethasone valerate 0.1% cream alone in the treatment of vitiligo patients. Adv Biomed Res. 2017; 6:34.

13. Armario-Hita JC, Pereyra-Rodriguez J, Silvestre JF, Ruiz –Villaverde R, Valero A, Izu-Belloso R, et al. Treatment of moderate-to-severe Atopic dermatitis with dupilumab in real clinical practice. A multicentre, retrospective case series. B J Dermatol. 2019: 181(5): 1072-1074

14. Seegräber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018; 11(5): 467- 474.

15. Gooderham MJ, Hong HC, Eshtiaghi P, Papp K. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018; 78(3): S28-S36.

16. Pérez Atamoros FM, Alcalá Pérez D, Asz Sigall D, Ávila Romay A, Barba Gastelum J , de la Peña Salcedo J. Evidence-based treatment for gynoid lipodystrophy: A review of the recent literature. J Cosmet Dermatology. 2018; 17(6):977-983.

17. Zerini I, Sisti A, Cuomo R, Ciappi S, Russo F, Brandi C,et al. Cellulite treatment: a comprehensive literature review. J Cosmet Dermatol. 2015; 14(3): 224-240.

18. Rossi AM, Katz BE. A modern approach to the treatment of cellulite. Dermatol Clin, 2014; 32(1): 51-59.

19. Zouboulis CC, Dessinioti C, Tsatsou F, Gollnick H. Anti-acne drugs in phase 1 and 2 clinical trials. Expert Opin Invest Drugs. 2017; 26(7): 813-823.

20. Tan J, Thiboutot D, Popp G, Gooderham M, Lynde C, Del Rosso J, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019; 80(6): 1691-1699.

21. Trifu V, Tiplica GS, Naumescu E, Zalupca L, Moro L, Celasco G. Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, doubleblind comparative study vs. placebo and tretinoin 0· 05% cream. Br J Dermatol. 2011; 165(1):177-183.

22. Videira IF, Moura DF, Magina S. Mechanisms regulating melanogenesis. An Bras Dermatol. 2013; 88(1): 76-83.

23. D'Mello SA, Finlay GJ, Baguley BC, Askarian-Amiri M. Signaling pathways in melanogenesis. Int J Mol Sci. 2016; 17(7):1144

24. Yuan XH, Jin ZH. Paracrine regulation of melanogenesis. Br J Dermatol. 2018; 178(3): 632-639.

25. Eagleston LRM, Kalani NK, Patel RR, Flaten H, Dunnick C, DellaValle R. Cannabinoids in dermatology: A scoping review. Dermatol Online J. 2018; 24(6)

26. Moya AI, Ruiz-Rodríguez R. Eficacia y seguridad de los cannabinoides tópicos en dermatología. Piel. 2019; 34(5): 313-315.

27. Caterina MJ. TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation. ACS Chem Neurosci. 2014: 5(11): 1107-1116.

28. Yélamos O, Braun RP, Liopyris K, Wolner Z, Kerl K, Gerami P,et al. Dermoscopy and dermatopathology correlates of cutaneous neoplasms. J Am Acad Dermatol. 2019; 80(2): 341-363.

29. Lallas A, Apalla Z, Ioannides D, Lazaridou E, Kyrgidis A, Broganelli P, et al. Update on dermoscopy of Spitz/Reed naevi and management guidelines by the International Dermoscopy Society. Br J Dermatol. 2017; 177(3): 645-655.

30. Yélamos O, Navarrete-Dechent C, Marchetti MA, Rogers T, Apalla Z, Bahadoran P, et al. Clinical and dermoscopic features of cutaneous BAP1- inactivated melanocytic tumors: Results of a multicenter case-control study by the International Dermoscopy Society. J Am Acad Dermatol. 2019; 80(6):1585-1593.